{"id":3731,"date":"2021-05-17T05:30:25","date_gmt":"2021-05-17T09:30:25","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/"},"modified":"2026-09-24T00:07:21","modified_gmt":"2026-09-24T04:07:21","slug":"gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/","title":{"rendered":"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration"},"content":{"rendered":"\n<strong>Paris, France, le 17 mai 2021, 7h30 CEST<\/strong> \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration, en remplacement de Natalie Mount. Mme de Craecker rejoint le Conseil en qualit\u00e9 d\u2019administrateur ind\u00e9pendant.\n\n<em>\u00ab Je suis particuli\u00e8rement ravie de rejoindre l&rsquo;\u00e9quipe de GenSight dans cette p\u00e9riode de transformation d&rsquo;une soci\u00e9t\u00e9 de R&amp;D vers une organisation commerciale avec LUMEVOQ, leur principal produit pour le traitement de la NOHL, en cours d\u2019enregistrement par l&rsquo;EMA<\/em><em>, <\/em><em>\u00bb<\/em> d\u00e9clare <strong>Fran\u00e7oise de Craecker<\/strong>. \u00ab\u00a0<em>Il me tarde de travailler avec l&rsquo;\u00e9quipe de direction et le conseil d&rsquo;administration afin de mettre LUMEVOQ \u00e0 la disposition des patients dans l\u2019attente, le plus largement et le plus rapidement possible.\u00a0\u00bb<\/em>\n\n\u00c0 son dernier poste, Fran\u00e7oise dirigeait la r\u00e9gion Europe, Moyen-Orient et Afrique (EMEA) chez AveXis, acquise par Novartis. Elle a mis en place l&rsquo;\u00e9quipe multifonctionnelle qui a lanc\u00e9 Zolgensma, la premi\u00e8re th\u00e9rapie g\u00e9nique en une seule injection pour le traitement de l&rsquo;atrophie musculaire spinale en Europe, au Moyen-Orient et en Afrique. Elle a ouvert la voie \u00e0 l&rsquo;approbation, \u00e0 la distribution, \u00e0 l&rsquo;acc\u00e8s au march\u00e9 et \u00e0 la commercialisation, travaillant avec les autorit\u00e9s sur des voies de financement innovantes et un acc\u00e8s pr\u00e9coce. Elle a \u00e9galement \u00e9tabli une large pr\u00e9sence sur les principaux march\u00e9s europ\u00e9ens et un r\u00e9seau de distributeurs au Moyen-Orient et dans les autres pays europ\u00e9ens.\n\nAvant de rejoindre AveXis, Fran\u00e7oise dirigeait les op\u00e9rations europ\u00e9ennes de Raptor Pharmaceuticals \u00e0 la phase critique du passage de la R&amp;D \u00e0 la commercialisation de leur principal produit dans la cystinose. Auparavant, elle faisait partie de l&rsquo;\u00e9quipe de lancement du premier m\u00e9dicament orphelin approuv\u00e9 en Europe, et a occup\u00e9 diff\u00e9rents postes \u00e0 responsabilit\u00e9s croissantes au sein de Shire Human Genetics. Elle a \u00e9galement dirig\u00e9 diverses \u00e9quipes strat\u00e9giques et op\u00e9rationnelles, au niveau local et mondial pendant 14 ans.\n\nFran\u00e7oise est titulaire d&rsquo;un Master en Sciences de la Facult\u00e9 de M\u00e9decine de l&rsquo;Universit\u00e9 de Louvain (Belgique).\n\n<em>\u00ab Alors que nous travaillons \u00e0 la construction de notre nouvelle structure commerciale en Europe, je sais que la contribution et le soutien de Fran\u00e7oise seront d\u00e9terminants pour nous aider \u00e0 lancer avec succ\u00e8s LUMEVOQ l&rsquo;ann\u00e9e prochaine<\/em><em>, <\/em><em>\u00bb<\/em> a comment\u00e9 <strong>Bernard Gilly<\/strong>, co-fondateur et Directeur G\u00e9n\u00e9ral de GenSight Biologics. \u00ab\u00a0<em>Le Conseil se joint \u00e0 moi pour remercier Natalie pour son soutien et sa contribution au cours des 4 derni\u00e8res ann\u00e9es.\u00a0\u00bb<\/em>\n\n&nbsp;\n<h3><strong>\u00c0 propos de GenSight\u00a0Biologics<\/strong><\/h3>\nGenSight Biologics S.A. (GenSight Biologics) est une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central. Le portefeuille de recherche de GenSight Biologics s\u2019appuie sur deux plates-formes technologiques : le ciblage mitochondrial (<em>Mitochondrial Targeting Sequence<\/em>, ou MTS) et l\u2019optog\u00e9n\u00e9tique, visant \u00e0 pr\u00e9server ou restaurer la vision chez les patients atteints de maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine. En utilisant son approche de th\u00e9rapie g\u00e9nique, les candidats m\u00e9dicaments de GenSight Biologics sont destin\u00e9s \u00e0 offrir aux patients une r\u00e9cup\u00e9ration visuelle fonctionnelle durable apr\u00e8s une seule injection intra-vitr\u00e9enne dans chaque \u0153il. D\u00e9velopp\u00e9 dans le traitement de la neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL), le principal produit candidat de GenSight Biologics, LUMEVOQ<sup>\u00ae<\/sup> (GS010 ; lenadogene nolparvovec), est actuellement en cours d&rsquo;instruction pour un enregistrement en Europe, et en phase III pr\u00e9alablement au d\u00e9p\u00f4t de la demande d\u2019autorisation de mise sur le march\u00e9 aux Etats-Unis (<em>Biologics License Application<\/em> [BLA]).\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 17 mai 2021, 7h30 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Fran\u00e7oise de Craecker \u00e0 son [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[79],"news-type":[76],"post-year":[],"class_list":["post-3731","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-company-and-personnel","news-type-corporate"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 17 mai 2021, 7h30 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Fran\u00e7oise de Craecker \u00e0 son [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-17T09:30:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:07:21+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration\",\"datePublished\":\"2021-05-17T09:30:25+00:00\",\"dateModified\":\"2026-09-24T04:07:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/\"},\"wordCount\":678,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/\",\"name\":\"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-05-17T09:30:25+00:00\",\"dateModified\":\"2026-09-24T04:07:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2021\\\/05\\\/17\\\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration - GenSight Biologics","og_description":"Paris, France, le 17 mai 2021, 7h30 CEST \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui la nomination de Fran\u00e7oise de Craecker \u00e0 son [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/","og_site_name":"GenSight Biologics","article_published_time":"2021-05-17T09:30:25+00:00","article_modified_time":"2026-09-24T04:07:21+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration","datePublished":"2021-05-17T09:30:25+00:00","dateModified":"2026-09-24T04:07:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/"},"wordCount":678,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/","name":"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2021-05-17T09:30:25+00:00","dateModified":"2026-09-24T04:07:21+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2021\/05\/17\/gensight-biologics-nomme-francoise-de-craecker-a-son-conseil-dadministration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics nomme Fran\u00e7oise de Craecker \u00e0 son Conseil d\u2019administration"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=3731"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/3731\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=3731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=3731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=3731"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=3731"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=3731"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=3731"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=3731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}